- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05367336
Platelet Reactivity With Fentanyl, Morphine, or no Narcotic
October 27, 2023 updated by: Spectrum Health - Lakeland
A Comparison of PLAtelet Response to Aspirin Between Emergency Department Patients With Chest Pain Receiving Fentanyl or Morphine (PLAAFM)
The goal is to determine whether fentanyl and morphine have similar effects in reducing aspirin's effect upon platelets in emergency department patients with chest discomfort.
Morphine has been shown to worsen outcomes in heart attack patients due to reduction of oral anti-platelet agent effectiveness and so many providers have switches to using fentanyl.
However, it is largely unknown whether fentanyl has similar effects.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Patients presenting to the emergency department with chest discomfort who are being administered aspirin will be offered enrollment in this study.
At the time of their zero and two hour troponin we will also draw platelet aggregration studies to determine the effects of aspirin upon platelets.
Narcotic medicines slow the absorption of aspirin.
Morphine has therefore been shown to decrease the effectiveness of aspirin.
Many providers therefore use fentanyl instead, however little is known about the effects of fentanyl upon aspirin.
We will therefore compare the platelet reactivity of patients receiving morphine, fentanyl, or no narcotics
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Monique Luna
- Phone Number: 2699858679
- Email: monique.allen@spectrumhealth.org
Study Locations
-
-
Michigan
-
Saint Joseph, Michigan, United States, 49085
- Recruiting
- Spectrum Health Lakeland
-
Contact:
- Monique Luna, BS
- Phone Number: 269-985-8679
- Email: monique.allen@spectrumhealth.org
-
Contact:
- Matt Hysell, MD
- Email: matthew.hysell@spectrumhealth.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Adult Emergency Department patients undergoing 0 and 2 hour troponin testing
- administered aspirin within 30 minutes of the initial blood draw.
- patient presented via private vehicle
- provide informed consent
Exclusion Criteria:
- Patients not expected to get a 2 hour troponin;
- patients already on aspirin, clopidogrel, or stronger anti-coagulants;
- patients who arrived via EMS (Emergency Medical Services) given it can be difficult to find the run reports to determine whether patient received fentanyl in the pre-hospital period;
- pregnant patients;
- patients on chronic narcotics;
- patients already once enrolled in this study,
- inability to provide consent in English
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
not receiving any narcotics
|
|
Experimental: Morphine
the second group will be those receiving morphine
|
second group will be receiving morphine
|
Experimental: Fentanyl
the 3rd group will be those receiving fentanyl
|
third group receiving fentanyl
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
platelet aggregation
Time Frame: 2 hours
|
arachidonic acid platelet aggregation activity
|
2 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 31, 2022
Primary Completion (Estimated)
May 1, 2024
Study Completion (Estimated)
May 1, 2024
Study Registration Dates
First Submitted
September 23, 2021
First Submitted That Met QC Criteria
May 4, 2022
First Posted (Actual)
May 10, 2022
Study Record Updates
Last Update Posted (Actual)
October 31, 2023
Last Update Submitted That Met QC Criteria
October 27, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EGME#04-2021
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Platelet Reactivity
-
Taipei City HospitalCompletedPRU(Platelet Reactivity Unit) | APT(Antiplatelet Therapy) | HOTPR(High on Treat Platelet Reactivity)Taiwan
-
Ottawa Heart Institute Research CorporationCompleted
-
Rabin Medical CenterUnknownPlatelet Reactivity | Dual Antiplatelet TherapyIsrael
-
University of PatrasCompletedPlatelet ReactivityGreece
-
First Affiliated Hospital of Harbin Medical UniversityUnknownPlatelet ReactivityChina
-
University of PatrasCompleted
-
University of PatrasCompletedPlatelet ReactivityGreece
-
Gyeongsang National University HospitalUnknownCoronary Artery Stenosis | Maximal Platelet Aggregation | Late Platelet Aggregation | High Post-Treatment Platelet ReactivityKorea, Republic of
-
Shenyang Northern HospitalUnknownAcute Coronary Syndrome | Platelet Reactivity | Antiplatelet TherapyChina
Clinical Trials on Morphine
-
Indiana UniversityCompletedNeonatal Abstinence Syndrome | Neonatal Opioid Withdrawal Syndrome | Neonatal Opioid WithdrawalUnited States
-
Javelin PharmaceuticalsCompleted
-
Javelin PharmaceuticalsCompletedPain, PostoperativeUnited States
-
University of MonastirCompletedTitrated Versus High and Low Dose Nebulized Morphine to Reduce Pain in Emergency Settings (TIMORNEB)Acute Pain | Post-Traumatic HeadacheTunisia
-
Mahidol UniversityCompletedLung Diseases | Solitary MassThailand
-
University of Colorado, DenverCompletedScoliosis | Pain Management | Spinal FusionUnited States
-
Cukurova UniversityCompleted
-
Javelin PharmaceuticalsCompletedPost-Operative Pain | Third Molar Extraction
-
University College Hospital GalwayCompletedPain, Postoperative | Arthroplasty, Replacement, Knee
-
Rijnstate HospitalCompletedTotal Hip Replacement